J. Craig Venter's Human Longevity Inc. has struck a deal to provide exome sequencing services to the customers of a South Africa-based insurance firm. HLI is charging a meager $250 per exome, but in addition to the cash will get one of the other things it wants: data.
J. Craig Venter's Human Longevity (HLI) is teaming up with South African insurer Discovery Health to offer a $250 full exome sequencing product to customers, cashing in on the consumer diagnostics trend while delivering on its human genome sequencing ambitions.
J. Craig Venter's Human Longevity Inc. (HLI) has appointed a chief operating officer to manage its burgeoning genome sequencing operation. Mark Winham has taken up the position, jumping ship from drug-testing lab Millennium Health, where he also served as COO.
J. Craig Venter's Human Longevity, Inc., is working toward new deals with biopharma companies. And the completion of the agreements could lead to a ramping up of HLI's already massive sequencing capacity.
J. Craig Venter's Human Longevity Inc. (HLI) has struck a deal with the Cleveland Clinic to access blood samples. The initial focus of the deal is on the sequencing and analysis of samples in Cleveland Clinic's GeneBank.
Feedback from an early-access program for Synthetic Genomics' personal DNA workstation has started to emerge. And the initial news is positive, with a researcher at the University of California, San Francisco, reporting that the device is cutting the time and money it takes to synthesize DNA.
Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.
A fresh wave of biopharma companies are partnering and investing in genome sequencing companies to integrate their data into the drug development process. The latest deal on this front pairs Roche with startup Human Longevity.
J. Craig Venter's Human Longevity, Inc. has added another piece to the data tapestry it is creating. The new addition is a registry of 11,000 twins, complete with phenotypic information and paired samples.
J. Craig Venter has made new hires at two of his companies.